|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing Craniotomy显示文摘 | Alex Bekker Mary Sturaitis Marc Bloom Mario Moric John Golfinos Erik Parker Ramesh Babu Abishabeck Pitti | 2008 | Anesthesia & Analgesia2008，，4： | 1 |
| 2 | Change in management of predicted difficult airways following introduction of video laryngoscopes显示文摘AIM To determine if video laryngoscopy(VL) has significantly impacted management of difficult airways by decreasing the rate of awake fiberoptic intubation(FOI). METHODS Anesthetic records of 3723 patients who underwent general anesthesia at Rush University Medical Center were reviewed over a 2-mo period prior to the introduction of VLs in 2009('pre-VL' group) and over the same 2-mo period after the introduction of VLs in 2012('postVL' group). Patient records with predicted difficult air-ways based on pre-operative airway examination were analyzed. The primary outcome was rate of awake FOI.RESULTS To control for possible factors that may influence the FOI rate, a logistic regression was performed with these factors included as covariates. The rate of awake FOI was 13.1% in pre-VL group compared to 9.0% in post-VL group. Although this decrease was not statistically significant individually(P = 0.1768), it showed a trend toward significance when covariates were accounted for(P = 0.0910). Several factors predicting a higherlikelihood of awake FOI were found to be statistically significant: Morbid obesity(larger BMI P = 0.0154, OR = 1.5 per 10 point BMI increase), male gender(P = 0.0026, OR = 3.0) and a higher el-Ganzouri airway score(P = 0.0007, OR = 1.5). Although VLs were seen to be used to intubate 51% of predicted difficult airways, the rate of awake FOI has not significantly changed.CONCLUSION Although VL may continue to grow in popularity, the most difficult airways are still managed using awake FOI. | Mary Jarzebowski Arvind Rajagopal Bryce Austell Mario Moric Asokumar Buvanendran | 2018 | World Journal of Anesthesiology2018，7，1： | 1 |
| 3 | Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions显示文摘 | Antonio Colombo Jeffrey W. Moses Marie Claude Morice Josef Ludwig David R. Holmes Vassilis Spanos Yves Louvard Benny Desmedt Carlo Di Mario Martin B. Leon | 2004 | Circulation: Journal of the American Heart Association2004，，10： | 1 |
| 4 | The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing Craniotomy显示文摘 | Alex Bekker Mary Sturaitis Marc Bloom Mario Moric John Golfinos Erik Parker Ramesh Babu Abishabeck Pitti | 2008 | Anesthesia & Analgesia2008，，4： | 1 |
| 5 | Predictors for moderate to severe acute postoperative pain after total hip and knee replacement显示文摘 | Spencer S. Liu Asokumar Buvanendran James P. Rathmell Mona Sawhney James J. Bae Mario Moric Stephen Perros Ashley J. Pope Lazaros Poultsides Craig J. Della Valle Naomi S. Shin Colin J. L. McCartney Yan Ma Mahendrakumar Shah Monica J. Wood Smith C. Manion | 2012 | International Orthopaedics2012，，11： | 1 |
| 6 | Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties显示文摘 | Nicholas T. Ting Mario M. Moric Craig J. Della Valle Brett R. Levine | 2012 | The Journal of Arthroplasty2012，，10： | 1 |
| 7 | Operative Treatment of Early Peri-Prosthetic Femur Fractures Following Primary Total Hip Arthroplasty显示文摘 | Neil P. Sheth Nicholas M. Brown Mario Moric Richard A. Berger Craig J. Della Valle | 2012 | The Journal of Arthroplasty2012，，： | 1 |
| 8 | 生物可降解多聚体biolimus洗脱支架与不可降解多聚体西罗莫司洗脱支架用于冠状动脉血运乖建(LEADERS):一项随机非劣效性试验显示文摘背景初步研究表明,从生物可降解多聚体中释出biolimus(西罗莫司类似物)的一种新型洗脱支架有望获得良好的临床效果。本研究比较了biolimus洗脱支架(具有生物可降解多聚体)和西罗莫司洗脱支架(具有不可降解多聚体)的安全性和疗效。方法作者在欧洲的10个研究中心进行了一项多中心、评估音设盲的非劣效性研究。1707例年龄≥18岁、患有慢性稳定性冠心病或急性冠状动脉综合征的患者经计算机产生的一组随机分配序列进行集中随机分组,分别接受biolimus,先脱支架(n=857)或西罗莫司洗脱支架(n=850)植入主要终点是在9个月内心脏性死亡、心肌梗死或具有临床指征的靶血管血运重建(TVR)的复合事件、采用意向治疗分析法对结果进行分析、随机抽取427例患者接受血管造影随访,主要结果指标为9个月时史巢内直径狭窄的百分比。本临床试验在ClinicalTrials.gov网站上注册,注册号为NCT00389220。结果对研究中所有随机分组的患者进行了分析。9个月时biolimus洗脱支架组在主要终点指标上并不劣于西罗莫司洗脱支架组[79例(9%)vs89例(11%),RR0.88,95%CI0.64~1.19,非劣效P=0.003,优势P=0.39]。心脏性死亡发生率[14例(1.6%)vs21例(2.5%),优势P=0.22]、心肌梗死发生率[49例(5.7%)vs39例(4.6%),P=0.30]以及具有临床指征的TVR实施率[38例(4.4%)vs547例(5.5%),P=0.29]在两组中相似.Biolimus洗脱支架组有168例(79%)患者的资料可用于血管造影随访,西罗莫司洗脱支架组有167例(78%)Biolimus洗脱支架组在支架内直径狭窄百分比上不劣于西罗莫司洗脱支架组(20.9%vs 23.3%,差值-2.2%.95%CI-6.0%~1.6%,非劣效P=0.001,优势P=0.26)、结论研究结果表明,从生物可降解多聚体中释出biolimus的洗脱支架安全有效,在对慢性稳定性冠心病或急性冠状动脉综合征患者进行治疗时,它可以取代从不可降解多聚体中释出西罗莫司的洗脱支架。 | Stephan Windecker Patrick W Serruys Simon Wandel Pawel Buszman Stanislaw Trznadel Axel Linke Karsten Lenk Thomas Ischinger Volker Klauss Franz Eberli Roberto Corti William Wijns Marie-Claude Morice Carlo di Mario Simon Davies Robert-Jan van Geuns Pedro Eerdmans Gerrit- Anne van Es Bernhard Meier Peter Jüni 刘少伟(译) | 2009 | 世界临床医学2009，3，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员